On March 30, 2019, Taimei Technology held a TrialOS® Drug R&D Cooperation Platform launch event at the InterContinental Shanghai Hongqiao NECC. More than 300 experts from clinical research institutions, pharmaceutical companies, and CROs attended the event.
Professor Li Ning, the director of the National Cancer Office in Tumor Hospital which belongs to Chinese Academy of Medical Sciences，Gu Jun，the director of New Drug Clinical Research Office of Shanghai Public Health Clinical Center and Hu Guoqiang，the CMO of Beta Pharma, addressed their speeches at the evente.
“In the digital trend of the life science industry, Taimei Technology aims to provide robust infrastructure for the industry, pave the information highway to support efficient operation of pharmaceuticals, and finally set up a reasonable, prosperous and efficient pharmaceutical ecosystem. Regarding collaboration as the core concept, TrialOS® Drug R&D Cooperation Platform eliminates information asymmetry through the data interaction, process collaboration and standard harmonization in clinical research. With the data-driven operation, TrialOS® integrates resources to achieve value upgrade and win-win for all parties. The platform can help sponsors accelerate the clinical research process, improve quality and reduce costs for institutions and researchers, reduce workload, improve work experience and undertake more research. Also, it provides CROs with more business opportunities, lowers the workload and promotes service quality and profitability,” said Zhao Lu, Chairman and CEO of Taimei Technology.
Jason Hu, general manager of Division of Platform Business, introduced that TrialOS® carries over 20 existing software developed by Taimei, forming a unified workbench, covering the entire clinical research process and connecting data, documents and processes in clinical research. Thus, online collaboration and efficient communication can be guaranteed among sponsors, sites, CROs and relevant parties. Big data-based project library, central database, subject database, researcher database, enterprise database and drug database will effectively promote the quality and progress during the processes of the clinical trials.
As important parts connecting authority ends on the TrialOS® Drug R & D platform, eSite Authority Management System and eTrial Phase I Ward System were officially unveiled on the same day. Mr. Zhang Hongwei, general manager of Division of Hospital Relations, introduced that based on TrialOS® platform’s capabilities, eSite and eTrial have the natural advantages of covering the entrie trial process, multi-party collaboration, open interconnection, human intelligence and mobile convenience. eSite is equipped with eight modules: project management, ethics management, quality control management, trial subject management, drug management, document management, training management, and personnel management. Directly connected to EDC, eTrial is coupled to external measurement equipment, mobile terminal data collection, and three modules of doctor advice management, sample management and trial subject management. eTrial improves the management capabilities and efficiency of the site to ensure compliance and controllable quality.